CINCINNATI, Ohio (February 19, 2013) – BioRx announced today the launch of a new physical therapy program to help patients, physicians, physical therapists, and health insurers manage the complications and costs of hemophilia-related joint damage. The program, called REBUILD, supports a patient’s physical therapy program at the local level.
Read the rest of this entry »
Cincinnati, Ohio (October 29, 2012) - BioRx, a national specialty pharmacy and infusion services provider, has been added to the limited distribution network for Zemaira® [alpha-1 proteinase inhibitor (human)]. Zemaira is indicated for chronic augmentation and maintenance therapy in individuals with alpha1-antitrypsin (AAT) deficiency and clinical evidence of emphysema. Read the rest of this entry »
Cincinnati, Ohio (July 11, 2012) — BioRx, a national specialty pharmacy and infusion services provider, has been added to the limited distribution network for Corifact® [Factor XIII Concentrate (Human)], manufactured by CSL Behring. Corifact is the only FDA-approved treatment for congenital Factor XIII (FXIII) deficiency, reported to be one of the rarest bleeding disorders in the world. Read the rest of this entry »
Cincinnati, Ohio (July 9, 2012) — BioRx announced today that it has acquired Coagulife Pharmacy, a specialized provider of clotting factor medications and supplies for the treatment of hemophilia and related bleeding disorders. Read the rest of this entry »
Cincinnati, Ohio (May 9, 2012) — In response to reports of a shortage of one C1 esterase inhibitor (C1-INH) product on the market, BioRx affirmed today that its supply of Berinert® (C1 esterase inhibitor, human) remains strong and can immediately accommodate increased demand. Read the rest of this entry »
Cincinnati, Ohio (September 12, 2011) - BioRx, a specialty pharmacy company, has received limited distribution rights from Shire Human Genetic Therapies, Inc. (“Shire HGT”) for its new drug, FIRAZYR® (icatibant injection), which received FDA approval on August 25, 2011. As the only FDA-approved self-injectable treatment for hereditary angioedema (HAE), FIRAZYR offers HAE patients an important new option for treating HAE attacks. Read the rest of this entry »
Philip Rielly and Eric Hill co-founded a small private company and they run it like a small private company. Every decision they make, they ask themselves, “Is this big-corporate stupid?” Read the rest of this entry »
